NAS:KZIA (Australia)  
Kazia Therapeutics Ltd logo

Kazia Therapeutics Ltd

$ 1.16 +0.03 (+2.65%) 10:08 PM EST
P/E:
At Loss
P/B:
1.56
Market Cap:
$ 17.43M
Enterprise V:
$ 15.58M
Volume:
15.50K
Avg Vol (2M):
445.88K
Also Trade In:
Volume:
15.50K
Market Cap $:
17.43M
PE Ratio:
At Loss
Avg Vol (2-Month):
445.88K
Enterprise Value $:
15.58M
PB Ratio:
1.56
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.
Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset 0.53
Interest Coverage No Debt
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0.04
Distress
Grey
Safe
Beneish M-Score 109.83
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 25.36
9-Day RSI 27.43
14-Day RSI 27.83
6-1 Month Momentum % -78.65
12-1 Month Momentum % -85.64

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.62
Quick Ratio 1.62
Cash Ratio 1.57

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -37.7

Financials (Next Earnings Date:2022-10-28 Est.)

KZIA's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:KZIA

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Embed

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 11.608
EPS (TTM) ($) -0.706
Beta 2.57
Volatility % 63.19
14-Day RSI 27.83
14-Day ATR ($) 0.153028
20-Day SMA ($) 1.383
12-1 Month Momentum % -85.64
52-Week Range ($) 1.04 - 12.28
Shares Outstanding (Mil) 15.03

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Kazia Therapeutics Ltd Filings

Document Form Filing Date
No Filing Data

Kazia Therapeutics Ltd Analysis

Share your research

Headlines

See More
No news.